{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:54:24Z","timestamp":1790009664688,"version":"4.0.1"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunotherapy is a promising treatment for advanced biliary tract cancer. However, the cost-effectiveness of pembrolizumab combined with gemcitabine and cisplatin remains unclear across different healthcare systems. This study evaluates its international cost-effectiveness in four countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A partitioned survival analysis model was developed using data from the KEYNOTE-966 trial to compare costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) of pembrolizumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone, from the healthcare system perspective of China, Japan, the United States, and Switzerland. Sensitivity and scenario analyses were used to identify key factors influencing the ICER.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The base-case analysis showed that pembrolizumab plus gemcitabine and cisplatin provided additional quality-adjusted life year gains of 0.14 in China, Japan, and the United States, and 0.15 in Switzerland. The incremental cost-effectiveness ratios in all four countries exceeded their respective willingness-to-pay thresholds, indicating limited cost-effectiveness. Sensitivity analysis identified drug price and utility value of progression-free survival as key factors. In the United States, Japan, and Switzerland, an 80\u201395% reduction in pembrolizumab\u2019s price was necessary for cost-effectiveness, while in China, a reduction greater than 95% was required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite clinical benefits, pembrolizumab combined with chemotherapy for advanced biliary tract cancer is not cost-effective at current prices and willingness-to-pay thresholds. Adjusting drug pricing and healthcare policies is crucial for enhancing the global economic viability of this treatment strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2025.1597550","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T07:09:49Z","timestamp":1754896189000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Multinational cost-effectiveness analysis of pembrolizumab combined with chemotherapy as first-line treatment for advanced biliary tract cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuxuan","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanrui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.31083\/j.fbl2706185","article-title":"The state of therapy modalities in clinic for biliary tract cancer","volume":"27","author":"Chen","year":"2022","journal-title":"Front Biosci (Landmark Ed)"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S0140-6736(05)67530-7","article-title":"Cholangiocarcinoma","volume":"366","author":"Khan","year":"2005","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/14737140.2025.2489651","article-title":"The effectiveness and safety of therapies for hepatocellular carcinoma with tumor thrombus in the hepatic vein, inferior vena cava and\/or right atrium: a systematic review and single-arm meta-analysis","volume":"25","author":"Wang","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1519999","DOI":"10.3389\/fimmu.2024.1519999","article-title":"Tumor-associated lymphatic vessel density is a postoperative prognostic biomarker of hepatobiliary cancers: a systematic review and meta-analysis","volume":"15","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.pan.2018.09.004","article-title":"Dilemma of elevated CA 19-9 in biliary pathology","volume":"18","author":"Tsen","year":"2018","journal-title":"Pancreatology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/cam4.299","article-title":"Cisplatin\/gemcitabine or oxaliplatin\/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review","volume":"3","author":"Fiteni","year":"2014","journal-title":"Cancer Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma","volume":"34","author":"Daud","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1007\/s00535-023-02041-3","article-title":"Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan","volume":"58","author":"Morimoto","year":"2023","journal-title":"J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung Cancer: randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1447828","DOI":"10.1080\/16549716.2018.1447828","article-title":"On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review","volume":"11","author":"Cameron","year":"2018","journal-title":"Glob Health Action"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jval.2019.10.005","article-title":"Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system","volume":"23","author":"Hasegawa","year":"2020","journal-title":"Value Health"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.annonc.2020.01.007","article-title":"A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definetive radiochemotherapy in Switzerland","volume":"31","author":"Panje","year":"2020","journal-title":"Ann Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"869960","DOI":"10.3389\/fpubh.2022.869960","article-title":"Cost-effectiveness analysis of five systemic treatments for Unresectable hepatocellular carcinoma in China: an economic evaluation based on network Meta-analysis","volume":"10","author":"Zhao","year":"2022","journal-title":"Front Public Health"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1016\/j.vaccine.2009.06.035","article-title":"WHO guide for standardisation of economic evaluations of immunization programmes","volume":"28","author":"Walker","year":"2010","journal-title":"Vaccine"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s40273-023-01305-3","article-title":"Cost effectiveness and budget impact of Nivolumab plus Ipilimumab versus platinum plus Pemetrexed (with and without bevacizumab) in patients with Unresectable malignant pleural mesothelioma in Switzerland","volume":"41","author":"Barbier","year":"2023","journal-title":"PharmacoEconomics"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1080\/13696998.2020.1830781","article-title":"Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan","volume":"23","author":"Paly","year":"2020","journal-title":"J Med Econ"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1393559","DOI":"10.3389\/fphar.2024.1393559","article-title":"Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US","volume":"15","author":"Luo","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1186\/s12885-023-11255-w","article-title":"Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China","volume":"23","author":"Zheng","year":"2023","journal-title":"BMC Cancer"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1111\/liv.15699","article-title":"Immune checkpoint inhibitor for patients with advanced biliary tract cancer: a cost-effectiveness analysis","volume":"43","author":"Zhu","year":"2023","journal-title":"Liver Int"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e7243","DOI":"10.1002\/cam4.7243","article-title":"Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: a cost-effectiveness analysis","volume":"13","author":"Lian","year":"2024","journal-title":"Cancer Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s13023-023-02925-w","article-title":"First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis","volume":"18","author":"Yang","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ygyno.2021.05.038","article-title":"Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: a Markov analysis","volume":"162","author":"Ackroyd","year":"2021","journal-title":"Gynecol Oncol"},{"key":"ref28","year":"2024"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12992-019-0524-4","article-title":"Japan: achieving UHC by regulating payment","volume":"15","author":"Ikegami","year":"2019","journal-title":"Glob Health"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"PO.19.00291","DOI":"10.1200\/PO.19.00291","article-title":"Precision oncology and the universal health coverage system in Japan","volume":"3","author":"Ebi","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1046424","DOI":"10.3389\/fpubh.2023.1046424","article-title":"Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer","volume":"11","author":"Ye","year":"2023","journal-title":"Front Public Health"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e2413938","DOI":"10.1001\/jamanetworkopen.2024.13938","article-title":"International cost-effectiveness analysis of durvalumab in stage III non-small cell lung cancer","volume":"7","author":"Kareff","year":"2024","journal-title":"JAMA Netw Open"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.6004\/jnccn.2018.7267","article-title":"Policy strategies for the \u201cnew normal\u201d in healthcare to ensure access to high-quality cancer care","volume":"17","author":"Schatz","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"ref34","year":"2024"},{"key":"ref35","year":"2024"},{"key":"ref36","year":"2024"},{"key":"ref37","year":"2024"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.21037\/atm-21-1803","article-title":"Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China","volume":"9","author":"Yang","year":"2021","journal-title":"Ann Transl Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40261-023-01311-5","article-title":"Cost-effectiveness analysis of Atezolizumab versus platinum-based chemotherapy as first-line treatment for patients with Unresectable advanced non-small cell lung Cancer with PD-L1 expression status in Japan","volume":"43","author":"Chisaki","year":"2023","journal-title":"Clin Drug Investig"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e0196007","DOI":"10.1371\/journal.pone.0196007","article-title":"Assessment of costs associated with adverse events in patients with cancer","volume":"13","author":"Wong","year":"2018","journal-title":"PLoS One"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"w20170","DOI":"10.4414\/smw.2019.20170","article-title":"Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland","volume":"149","author":"Arjun","year":"2019","journal-title":"Swiss Med Wkly"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40261-021-01017-6","article-title":"Cost-effectiveness analysis of atezolizumab plus nab-paclitaxel for advanced PD-L1 positive triple-negative breast cancer in Japan","volume":"41","author":"Chisaki","year":"2021","journal-title":"Clin Drug Investig"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s41669-023-00445-8","article-title":"Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant Pembrolizumab in patients with high-risk, early-stage, triple-negative breast Cancer in Switzerland","volume":"8","author":"Favre-Bulle","year":"2024","journal-title":"Pharmacoecon Open"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/cam4.2793","article-title":"Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC","volume":"9","author":"Wan","year":"2020","journal-title":"Cancer Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12962-023-00429-9","article-title":"Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial","volume":"21","author":"Zhao","year":"2023","journal-title":"Cost Eff Resour Alloc"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10198-023-01602-w","article-title":"Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan","volume":"25","author":"Kashiwa","year":"2024","journal-title":"Eur J Health Econ"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1111\/j.1440-1746.2010.06404.x","article-title":"Economic evaluation of sorafenib in unresectable hepatocellular carcinoma","volume":"25","author":"Carr","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"e0126984","DOI":"10.1371\/journal.pone.0126984","article-title":"Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C","volume":"10","author":"Pfeil","year":"2015","journal-title":"PLoS One"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"871262","DOI":"10.3389\/fphar.2022.871262","article-title":"Cost-effectiveness analysis of capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.clinthera.2020.05.013","article-title":"Comparative cost-effectiveness of aflibercept and ramucirumab in combination with irinotecan and fluorouracil-based therapy for the second-line treatment of metastatic colorectal cancer in Japan","volume":"42","author":"Kashiwa","year":"2020","journal-title":"Clin Ther"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.6004\/jnccn.2020.7796","article-title":"Cost-effectiveness analysis of durvalumab plus chemotherapy in the first-line treatment of extensive-stage small cell lung cancer","volume":"19","author":"Ding","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3892\/mco.2017.1278","article-title":"Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer","volume":"7","author":"Kurimoto","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1080\/13696998.2022.2071066","article-title":"Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China","volume":"25","author":"Rui","year":"2022","journal-title":"J Med Econ"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s12029-024-01106-7","article-title":"Comparative cost-effectiveness of gemcitabine and cisplatin in combination with S-1, durvalumab, or pembrolizumab as first-line triple treatment for advanced biliary tract cancer","volume":"55","author":"Kashiwa","year":"2024","journal-title":"J Gastrointest Cancer"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"e210037","DOI":"10.1001\/jamanetworkopen.2021.0037","article-title":"Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma","volume":"4","author":"Su","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/jjco\/hyab086","article-title":"Cost-effectiveness of trifluridine\/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan","volume":"51","author":"Takushima","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.lungcan.2018.11.029","article-title":"Cost-effectiveness of afatinib, gefiti-nib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China","volume":"127","author":"Gu","year":"2019","journal-title":"Lung Cancer"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"e218065","DOI":"10.1001\/jamanetworkopen.2021.8065","article-title":"Nivolumab vs pembrolizumab for treatment of US patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a network meta-analysis and cost-effectiveness analysis","volume":"4","author":"Pei","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1597550\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T07:09:50Z","timestamp":1754896190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1597550\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":58,"alternative-id":["10.3389\/fpubh.2025.1597550"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1597550","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"article-number":"1597550"}}